Novo Nordisk Shares Fall 6.3% After Latest Trial Results for Its Next-Generation Weight Loss Drug

Shares of Novo Nordisk Fell on Monday, after the danish pharmaceutical giant said its next-generation weight-loss drug cagrisema helped obese or overweight adults with type type type 2 diabetes Diabetes Diabetes Diabetes DIABETES DORPE after 68 weeks.

The company’s stock was down 6.3% at 11:22 AM London Time.

Novo Nordisk, which manufactures the fiercely Popular weight-live wegovy, Previously forecast Weight loss of 25% for patients who take cagrisema. In another late-trial result published in December, The Company Found Cagrisema Helped Patients Reduce their weight by 22.7% in that test.

Cagrise is being investigated by novo nordisk as a weight-loss drug for adults who are overweight or obese, as well as a treatment for adults with type 2 diabetes. The company currently expects to file for regulatory approval for Cagrise in the first Quarter of 2026.

Shares of US Rival Eli lillywhich makes weight-loss drug mounjaro, briefly jumped Higher after Novo Nordisk’s update on Monday, but was trading down 1.2% by 11:34 AM in London.

Markets have been hoping that cagrisema Could become a next-generation weight-loss drugThe treatment, injected Once Weekly, is a combination of Cagrilintide and semaglutide – the activity ingredient in Wegovy.

The phase 3 trial of Cagrise Had 1,206 Participants with a mean baseline body weight of 102kg (225 LB).

Despite a negative reaction to the results from investors on monday, novo nordisk touted the “Superor weight loss” achieved by of their weight thoughtout the 68-wheek period.

Novo Nordisk also said the drug appeared to have a “safe and well-tolerated profile,” With the most common side effect being mild to moderate gastrointestinal symptoms. These diminished over time, the company noted.

Last WeekNovo Nordisk launched an online pharmacy, novocare, to allow consumers to purchase wegovy directly from the company at a discounted price of $ 499 a month.

The success of its weight-loss drugs wegovy and ozepic have helped novo noordisk become One of the most valuable companies in the world,